Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,969 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam KC, Muñoz-Antonia T, Qu X, Eschrich S, Uramoto H, Tanaka F, Nasarre P, Gemmill RM, Roche J, Drabkin HA, Haura EB. Yoshida T, et al. PLoS One. 2016 Jan 20;11(1):e0147344. doi: 10.1371/journal.pone.0147344. eCollection 2016. PLoS One. 2016. PMID: 26789630 Free PMC article.
Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance.
Creelan BC, Gray JE, Tanvetyanon T, Chiappori AA, Yoshida T, Schell MJ, Antonia SJ, Haura EB. Creelan BC, et al. Among authors: yoshida t. Br J Cancer. 2019 Apr;120(8):791-796. doi: 10.1038/s41416-019-0428-3. Epub 2019 Mar 18. Br J Cancer. 2019. PMID: 30880334 Free PMC article. Clinical Trial.
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms.
Li J, Bennett K, Stukalov A, Fang B, Zhang G, Yoshida T, Okamoto I, Kim JY, Song L, Bai Y, Qian X, Rawal B, Schell M, Grebien F, Winter G, Rix U, Eschrich S, Colinge J, Koomen J, Superti-Furga G, Haura EB. Li J, et al. Among authors: yoshida t. Mol Syst Biol. 2013 Nov 5;9:705. doi: 10.1038/msb.2013.61. Mol Syst Biol. 2013. PMID: 24189400 Free PMC article.
Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
Yoshida T, Zhang G, Smith MA, Lopez AS, Bai Y, Li J, Fang B, Koomen J, Rawal B, Fisher KJ, Chen YA, Kitano M, Morita Y, Yamaguchi H, Shibata K, Okabe T, Okamoto I, Nakagawa K, Haura EB. Yoshida T, et al. Clin Cancer Res. 2014 Aug 1;20(15):4059-4074. doi: 10.1158/1078-0432.CCR-13-1559. Epub 2014 Jun 11. Clin Cancer Res. 2014. PMID: 24919575 Free PMC article.
Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase.
Okabe T, Okamoto I, Tsukioka S, Uchida J, Iwasa T, Yoshida T, Hatashita E, Yamada Y, Satoh T, Tamura K, Fukuoka M, Nakagawa K. Okabe T, et al. Among authors: yoshida t. Mol Cancer Ther. 2008 Mar;7(3):599-606. doi: 10.1158/1535-7163.MCT-07-0567. Mol Cancer Ther. 2008. PMID: 18347146
10,969 results
You have reached the last available page of results. Please see the User Guide for more information.